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ABSTRACT 
Cystoid macular edema is a condition that involves the macula, caused by an accumulation of extracellular 
fluid in the macular region with secondary formation of multiple cystic spaces. This condition is provoked 
by a variety of pathological conditions such as intraocular inflammation, central or branch retinal vein 
occlusion, diabetic retinopathy and most commonly following cataract extraction, hereditary retinal 
dystrophies, and topical or systemic assumption of drugs. Niacin is a vitamin preparation usually used for 
the treatment of lipid disorders. The treatment with niacin, alone or in combination with other lipid-
lowering agents, significantly reduces total mortality and coronary events and slows down the progression 
of and induces the regression of coronary atherosclerosis. Several cases of niacin-induced cystoid macular 
edema have been reported with different dosages. 
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INTRODUCTION 
Cystoid macular edema (CME) refers to swelling of the 
central part of the retina. The macula is responsible for 
detailed central vision. When the macula experiences 
swelling (edema), central vision is reduced. CME 
represents a common pathologic sequel of the retina and 
occurs in a variety of pathological conditions such as 
intraocular inflammation, central or branch retinal vein 
occlusion, diabetic retinopathy and most commonly 
following cataract extraction, hereditary retinal 
dystrophies, and topical or systemic assumption of drugs 
(1–2). 
 Several cases of niacin induced CME have been reported 
(3–6). The aim of this review is to show the use of niacin 




CME is a disorder that involves the central retina, caused 
by an accumulation of extracellular fluid in the macular 
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region with secondary formation of multiple cystic spaces 
(7). Histological studies show that radially orientated 
cystoid spaces consisting of ophthalmoscopically clear 
fluid are often clinically detectable in the macula area. 
These cysts seem to be areas of the retina in which the 
cells have been displaced (1). It is the result of cystic 
accumulation of extracellular intraretinal fluid in the 
outer plexiform and inner nuclear layers of the retina (8). 
The exact pathogenesis of CME remains uncertain. CME 
following disruption of the blood–retinal barrier (BRB) 
(9). When the BRB is damaged, fluid accumulates within 
the retina both intra- and extracellularly (10). Müller cells 
are thought to play an important role in acting as 
metabolic pumps that keep the macula dehydrated. 
However, intracellular fluid accumulation in the Müller 
cells may also occur in CME and further reduce macular 
retinal function. Vitreous traction may also play a part in 
the development of CME (11). Macular edema is the 
most frequent and severe complications of pars planitis, 
HLA-B27-associated acute anterior uveitis, sarcoidosis, 
birdshot retinochoroidopathy, Behcet’s syndrome, 
toxoplasmosis, Eales’ disease, idiopathic vitritis, Vogt-
Koyanagi-Harada syndrome, and scleritis (12–17). CME 
can follow cataract surgery in the Irvine–Gass syndrome 
(18), because after cataract surgery, inflammatory 
mediators from the anterior chamber diffuse posteriorly 
into the vitreous, causing leakage from the retinal 
vasculature (19–20). 
CME is the consequence of diabetic retinopathy (21). The 
edema in the macular area occurs secondary to an 
abnormal permeability of the capillaries surrounding the 
macula (failure of inner retinal blood barrier), and in turn 
to a failure in the outer retinal barrier (formed by the 
retinal pigmented epithelium) (22–24). Retinal vein 
obstructions (RVO) represent another cause of CME. 
Increased rigidity of a crossing artery because an 
atherosclerotic process has been suggested to cause 
compression of the underlying vein, provoking turbulent 
blood flow, endothelial damage, and thrombus 
formation (25). Likewise, a common vitreous adhesion at 
the obstruction site has also been reported, suggesting a 
possible role of vitreovascular traction in the etiology of 
some cases of BRVO (26–27). Atherosclerosis is a chronic 
low-grade inflammatory disorder and inflammation 
within the vascular wall contributes to the development 
of CME (28–29). Due to BRB breakdown secondary to 
damage at the tight junctions of endothelial cells, fluid 
diffusion from the occluded veins into the tissue can lead 
to CME (30). In addition, through such mechanisms, 
inflammatory responses and vascular dysfunction can all 
interact to cause retinal ischemia, which induces the 
expression of VEGF and others inflammatory agents (31), 
which participate in a complex chain of events that has 
yet to be fully defined (32–34). 
 
NIACIN: DEFINITION AND RULES 
Niacin (nicotinic acid) is a vitamin preparation usually 
used for the treatment of lipid disorders (35). Niacin 
favorably affects apolipoprotein (apo) B–containing 
lipoproteins (very-low-density lipoprotein [VLDL], low-
density lipoprotein [LDL], lipoprotein[a]) and increases 
apo A-I–containing lipoproteins (high-density lipoprotein 
[HDL]). There are new data on how niacin affects 
triglycerides (TG), vascular anti-inflammatory events, a 
particular niacin receptor in adipocytes and immune 
cells, and the characterization of a niacin transport 
system in liver and intestinal cells that is dependent on 
acidic pH, temperature, energy, Ca2+-calmodulin-
mediated pathways, but transport is sodium 
independent (36–42). Niacin directly and 
noncompetitively inhibits hepatocyte diacylglycerol 
acyltransferase–2, a key enzyme in TG synthesis that 
results in accelerated intracellular hepatic apo B 
degradation. Niacin reduces apolipoprotein C-III levels by 
inhibition of peroxisome-proliferator-activated receptor 
gamma co-activator 1b (PGC-1b), allowing greater apoE-
driven clearance of triglyceride-rich lipoproteins (43). 
Niacin is available in a variety of formulations: 
immediate-release (IR), slow-release (SR), extended-
release (ER) (44). Studies have demonstrated that ER 
provides lipid-modifying efficacy equivalent to that of IR 
niacin, but with less flushing, while avoiding the 
hepatotoxicity of other long-acting niacins (45–46). 
However, the use of niacin in patients with diabetes has 
been discouraged because high doses can worsen 
glycemic control (47). The discovery that niacin reduced 
free fatty acids (FFA) lead to suggestions that its primary 
effect was on peripheral lipolysis and that all other 
actions were secondary. This was reinforced by the 
discovery of the HM74⁄ GPR109A cyclic-G protein-
coupled receptor in adipose tissue (48) and niacin is a 
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specific ligand for this receptor which mediates the 
flushing response in dendritic cells and macrophages 
(49–50). Treatment with niacin, alone or in combination 
with other lipid-lowering agents, significantly reduces 
total mortality and coronary events and holds back the 
progression of and induces the regression of coronary 
atherosclerosis (37,51–52). 
Niacin improves endothelial function (53–54) and 
reduces progression of carotid intima-media thickness 
(cIMT) (55) and also had this effect in trials on top of 
statin-optimised LDL-C when used at a low dose of 1 g ⁄ 
day in the Arterial Biology for the Investigation of the 
Treatment Effects of Reducing Cholesterol (ARBITER)-2 
(& 3) trials (52,56). 
 
SYSTEMIC SIDE EFFECTS OF NIACIN 
The problem with niacin is the high incidence of flushing 
(57). The flushing is cutaneous and usually restricted to 
the face and chest and is also associated with a burning 
sensation and often generalized pruritus. It lasts 20–30 
min and habituates with exposure declining in both 
severity and frequency with time (58–59).  
Niacin-induced flushing appears to be due to the 
subcutaneous release of PGD2, which is mediated by 
niacin’s action as a pharmacologic ligand for the 
adipocyte and macrophage G protein–coupled nicotinic 
acid receptor GPR109A and appears to involve the 
formation of vasodilatory prostanoids (60–61). Epidermal 
Langerhans cells are essential mediators of the flushing 
response (62–65). Niacin also has adverse effects on 
some aspects of the metabolic syndrome: it is weight 
neutral and delivers a small blood pressure reduction 
(66) but it can increase glucose and HbA1c (67–69). 
This effect is often temporary (70) but in 5–10% patients 
with diabetes it can raise HbA1c by 0.5–1.0% even if the 
alteration of hypoglycaemic therapy occurs (71). Clinical 
studies suggest that the niacin can raise the plasma levels 
of uric acid and reduce the glucose tolerance. Dry skin 
and cutaneous hyperpigmentation (acanthosis nigricans) 
are also commonly reported (72). 
 
NIACIN AND OCULAR EFFECTS 
Many authors reported ocular side effect after therapy 
with niacin. Fraunfelder et al. (5) reported that 3 g or 
more per day of nicotinic acid, could cause blurred vision, 
eyelid edema, toxic amblyopia, proptosis, loss of 
eyelashes or eyebrow, superficial punctate keratitis and 
CME. Some cases of blurred vision were reported in the 
literature (73), and 18 cases were reported to the 
National Registry or the FDA spontaneous reporting 
system. In these cases, the average dose of niacin was 
1.5–2 g per day, with a duration of therapy varying from 
6 weeks to 1 year. Follow-up reported complete 
resolution of visual symptoms after discontinuing niacin. 
Dry eye was explained because this vitamin may be 
secreted and concentrated in human tears, thereby 
irritating an already dry eye. Niacin can cause ocular 
signs and symptoms reversible dose related, so if the 
patient wishes to continue this therapy, it may be 
feasible to reduce the dose of the drug (6). Cases of 
niacin related maculopathy there is a 10:1 male: female 
ratio. Most cases were in their third to fifth decade of life 
and were being treated with an average dose of 3–6 g of 
niacin per day. The etiology of niacin’s effect on the 
macula is unknown, A first hypothesis suggests that, in 
patients with vascular or inflammatory diseases, niacin 
induces the release of prostaglandins, causing the blood-
retinal barrier compromise with extracellular 
accumulation of fluid in many cystic spaces. This theory is 
not entirely accepted for the absence of fluorescein 
leakage (74). 
The second and the most reliable hypothesis supports 
that the niacin has a direct toxic effect on Müller cells, 
without disruption of the blood-retinal-barrier. 
Alterations in cellular metabolism cause intracellular fluid 
increase and swelling of these cells, with secondary 
formation of cysts between the glial spaces. After the 
discontinuation of niacin therapy, there is a complete 
regeneration of the Müller cells and their normal 
function (75–76). Reports from the literature (77) suggest 
that the onset of maculopathy ranges from 1 to 36 
months after initiation of relatively high-dose therapy (3 
g or more daily). There have also been reports of this 
condition with lower dosages (1.5 g daily) (3). This 
patient had increased the dosage of niacin to 3 g daily 
nearly 2 months before documentation of CME. In a 
previous case report a very low dose of niacin was 
administered (18 mg) and niacin maculopathy appears 4 
weeks later with a complete resolution after 
discontinuation of drug, confirming the relationship 
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between drug administration and macular edema 
appearance. In this patient, funduscopic examination 
showed bilateral macular edema, but no signs of diabetic 
or hypertensive retinopathy excluding the presence of 
other factors that may contribute to the capillary 
dysfunction associated with edema onset (78). At 
funduscopic examination, the foveomacular area had a 
peculiar aspect: the foveola takes on a bright yellow hue, 
similar to an exudate. Cysts primarily involve the foveal 
area, and they are smaller than those seen in post-
surgical or inflammatory CME (3). FA and OCT are useful 
to confirm the diagnosis. FA showed the absence of 
fluorescein leakage or vascular alteration, whereas OCT 
confirms the presence of cystic hyporeflective spaces in 
the outer plexiform and inner nuclear layers. The cystoid 
spaces were more numerous and larger in the outer 
plexiform layer compared with the inner nuclear layer. 
Indeed previous studies reported that the fluor-
angiographic pattern is atypical (79–81) (Fig. 1). 
 
 
Figure 1. On the left, there is an image of Stratus OCT 2 weeks after 
the start of niacin treatment. On the right fluorescein angiography of 
the same patient after 3 weeks after the beginning of niacin 
treatment with the typical absence of leakage also in later phases. 
 
Gass described reversible bilateral CME with no 
angiographic fluorescein leakage in 3 patients taking 
doses of niacin greater than 1.5 g daily to treat 
hyperlipidemia (6). Although Gass described transmitted 
hyper-fluorescence with a cartwheel pattern in the 
fluorescein angiograms of his patients, later reports 
described typical fluorescence in similarly affected 
patients (3). In all these cases, symptoms resolved over 4 
to 8 weeks following discontinuation of niacin. First-line 
treatment for CME of toxic origin, such as that induced 
by niacin, is the removal of the offending agent (77). In 
milder cases of maculopathy, symptoms have resolved 
within a few days of drug discontinuation. 
CONCLUSION 
It was shown that the incidence of niacin maculopathy 
has been estimated to occur in 0.67% of patients being 
treated for hyperlipidemia. Studies have shown that even 
small doses of niacin cause CME. Patients with ocular 
symptoms such as blurred vision, decrease in visual 
acuity and metamorphopsia, should be immediately go 
to an ophthalmologist and stop the assumption of 
nicotinic acid before the onset of maculopathy. Niacin 
should be used with caution and under medical 
monitoring or periodic examination. Further studies 
would be desirable to investigate the safety dose, 
pathophysiologic mechanisms or predisposing risk 
factors and the possible interaction with others agents 
that may cause niacin maculopathy. 
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